Affordable Access

Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis.

Authors
  • 1
Type
Published Article
Journal
The Journal of bone and joint surgery. American volume
Publication Date
Volume
84-A
Issue
8
Pages
1405–1412
Identifiers
PMID: 12177271
Source
Medline

Abstract

Currently, there is no approved drug therapy to prevent or inhibit periprosthetic osteolysis. Although preclinical studies have identified potential drug therapies (i.e., bisphosphonates), there is no evidence that these drugs can effectively treat aseptic loosening in patients. This is the first evidence that in vivo OPG gene therapy can be used to prevent wear debris-induced osteolysis.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments